Effect of long-term phosphodiesterase-5 inhibitor use on refractory lymphatic malformations in adult and teen patients

Lymphatic malformations (LMs) are rare congenital anomalies. LMs are often refractory to standard treatments, including surgical resection, debulking, and sclerotherapy. Use of sildenafil, a phosphodiesterase-5 inhibitor, for treatment of pediatric LMs has been reported with demonstrated benefit to...

Full description

Saved in:
Bibliographic Details
Published inJournal of vascular surgery. Venous and lymphatic disorders (New York, NY) Vol. 9; no. 1; pp. 258 - 261
Main Authors Nelson, Kari J., Antiquera, Pamela, Nelson, J. Stuart, Kelly, Kristen M., Abi-Jaoudeh, Nadine
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2021
Subjects
Adolescent
Adult
Female
Humans
Lymphatic Abnormalities - diagnosis
Lymphatic Abnormalities - drug therapy
Lymphatic malformation
Male
Phosphodiesterase 5 Inhibitors - therapeutic use
Phosphodiesterase-5 inhibitor
Remission Induction
Sildenafil
Sildenafil Citrate - therapeutic use
Treatment Outcome
Lymphatic malformation
Phosphodiesterase-5 inhibitor
Sildenafil
Online AccessGet full text

Cover

More Information
Summary:Lymphatic malformations (LMs) are rare congenital anomalies. LMs are often refractory to standard treatments, including surgical resection, debulking, and sclerotherapy. Use of sildenafil, a phosphodiesterase-5 inhibitor, for treatment of pediatric LMs has been reported with demonstrated benefit to some patients. This case series reports treatment of three patients (aged 14-37 years) suffering from complicated or refractory LMs with a low-dose oral phosphodiesterase-5 inhibitor, resulting in significant clinical improvement.
ISSN:2213-333X
2213-3348
DOI:10.1016/j.jvsv.2020.04.001